Arcutis Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
ZORYVE's strong Q4 performance and expanding indications have driven a significant increase in 2026 revenue guidance. Strategic investments in sales force and payer access, along with a robust pipeline and digital marketing, position the brand for continued growth and market leadership.
-
Q4 and full-year revenues exceeded expectations, driven by strong demand and market share gains in nonsteroidal topicals. Expansion of sales forces, Medicare access, and new pediatric indications are set to drive further growth, while robust IP and a promising pipeline support long-term outlook.
-
ZORYVE's growth is driven by expanding indications, evolving dermatology guidelines, and a broadened sales force. New studies in vitiligo and hidradenitis suppurativa could add $300M–$500M in risk-adjusted peak sales. ARQ-234 and business development efforts target durable, efficient expansion.
Fiscal Year 2025
-
Net product revenues grew 123% year-over-year to $372 million in 2025, driven by ZORYVE's strong adoption and label expansions. 2026 revenue guidance was raised to $480–495 million, with continued positive cash flow expected as investments in salesforce and pipeline accelerate.
-
Advanced topical therapies are rapidly gaining traction as safety concerns shift dermatology away from steroids. Strategic pricing and strong market access have driven robust growth, with pediatric approvals and pipeline expansion supporting future prospects. Cash flow breakeven is expected in Q4, and a strong IP portfolio underpins long-term value.
-
Q3 2025 saw 122% year-over-year revenue growth and a swing to net income, driven by ZORYVE's strong adoption and new launches. Cash flow breakeven is now expected in Q4 2025, with 2026 revenue guidance of $455M–$470M. ZORYVE's market share and pipeline expansion position it for sustained growth.
-
Strong Q2 sales growth continued into Q3 despite seasonality, driven by new product launches and deepening prescriber engagement. Expansion into pediatric atopic dermatitis and new indications is expected to fuel further growth, with a focus on non-steroidal therapies and lifecycle management.
-
ZORYVE continues to expand its market share with multiple new approvals and strong growth across both cream and foam formulations. Stable net pricing, expanding payer coverage, and a focus on deepening prescriber adoption support a path to cash flow break-even by 2026.
-
ZORYVE continues to gain traction as a safer, effective alternative to topical steroids, with strong commercial growth, expanding indications, and positive clinician feedback. Pipeline assets and lifecycle management aim to further strengthen market position, with cash flow break-even targeted for 2026.
-
ZORYVE delivered robust Q2 growth with $81.5M in revenue, driven by new indications and broad prescriber adoption. The company achieved positive operating cash flow, expanded its IP portfolio, and remains on track for cash flow break-even in 2026, despite Medicare Part D access delays.
-
Recent approvals and strong Q1 growth highlight momentum in advanced topical therapies, with further label expansions and government coverage expected to drive future gains. Pipeline assets ARQ-255 and ARQ-234 advance, while robust cash reserves support operations through 2026.
-
Q1 2025 saw 196% year-over-year revenue growth and strong prescription demand, with ZORYVE leading the branded nonsteroidal topical segment. Anticipated label expansions and robust insurance coverage are expected to drive continued growth, with cash break-even targeted for 2026.
-
The company highlighted strong 2024 growth driven by new launches and expanding coverage, with further momentum expected in 2025 from additional indications and broader insurance access. Confident in IP protection, financial stability, and pipeline progress, leadership sees a major opportunity as the market shifts from steroids to non-steroidal treatments.
-
Strong Q4 revenue growth and expanding product portfolio position the company for continued market share gains in dermatology. Strategic partnerships, new indications, and a robust IP portfolio support long-term growth, with break-even targeted for 2026.
-
Strong revenue momentum and operational efficiency set the stage for continued growth in 2025, driven by robust adoption of the ZORYVE portfolio and upcoming product approvals. Market expansion is focused on steroid conversion, pediatric atopic dermatitis, and increased Medicare access.
Fiscal Year 2024
-
Q4 and full-year 2024 saw robust revenue and prescription growth, driven by ZORYVE launches and expanding coverage. The company expects continued momentum in 2025, with new indications, strong refill rates, and a shift away from topical steroids, aiming for cash flow break-even in 2026.
-
Q3 2024 saw ZORYVE sales surge 452% year-over-year to $44.8M, driven by strong prescription growth, expanded indications, and improved gross-to-net. Medicaid coverage now spans 40% of the U.S., with Medicare Part D ramp expected in 2025.
-
Product launches for seborrheic dermatitis and atopic dermatitis are outperforming initial expectations, with strong demand, improved gross-to-net, and positive clinical feedback. Expansion into primary care via Kowa and new indications like scalp psoriasis are set to drive future growth.
-
Q2 2024 saw net product revenues of $30.9M, up 547% year-over-year, driven by strong Zoryve prescription growth and improved gross-to-net. Strategic expansion into atopic dermatitis and a new Kowa co-promotion set the stage for continued growth, with further revenue impact expected in 2025.
-
FDA approved ZORYVE Cream for mild to moderate atopic dermatitis in patients 6+, expanding its label and market reach. Clinical trials showed rapid, robust efficacy and a strong safety profile, with broad insurance coverage and a new co-promotion partnership expected to accelerate adoption.
-
Innovative dermatology products are driving strong growth, with recent launches in plaque psoriasis and seborrheic dermatitis, and an atopic dermatitis launch expected soon. Broad access strategies, rapid coverage gains, and a robust pipeline support a positive financial outlook.